IDEXX Laboratories, Inc. $IDXX Shares Sold by Quantitative Investment Management LLC

Quantitative Investment Management LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,148 shares of the company’s stock after selling 1,214 shares during the quarter. Quantitative Investment Management LLC’s holdings in IDEXX Laboratories were worth $1,657,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IDXX. SHP Wealth Management purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the third quarter worth approximately $26,000. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories during the second quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its holdings in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the last quarter. Finally, Wormser Freres Gestion boosted its holdings in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on IDXX shares. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. UBS Group boosted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $556.69 on Tuesday. The business’s 50-day simple moving average is $559.23 and its 200 day simple moving average is $572.70. The company has a market cap of $43.86 billion, a P/E ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the company posted $3.50 earnings per share. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.